March 7, 2026 •
The 1982 Tanner Report: Early Internal Evidence of NDMA Formation The 1982 Tanner Report stands as the foundational document in the case against GSK. It…
March 2, 2026 •
The April 2024 Public Disclosure: AstraZeneca's High Court Admission of TTS The Legal Admission In February 2024, a significant legal development occurred within the United…
February 22, 2026 • Ekalavya Hansaj
The 'Points Program': Gamifying Prescriptions in China's Public Hospitals Corporate corruption often manifests as complex financial instruments or shell companies. In the case of Pfizer…
February 13, 2026 • Ekalavya Hansaj
The Zyprexa Papers: A $1.4 Billion Off-Label Marketing Settlement The following investigative review examines the 2009 Zyprexa settlement involving Eli Lilly and Company. The Settlement…
February 13, 2026 • Ekalavya Hansaj
The Irish Subsidiary Scheme: Tracing the $1.4 Billion Tax Shelter Investigation Fiscal year 2012 marked a statistical anomaly for Bristol Myers Squibb. Financial ledgers displayed…
February 13, 2026 • Ekalavya Hansaj
The Humira Patent Thicket: Engineering Extended Exclusivity AbbVie Inc. did not just sell a drug. It constructed a legal fortress around one. Humira (adalimumab) stands…
February 11, 2026 • Ekalavya Hansaj
Antitrust Warfare: The Metsera 'Killer Acquisition' Lawsuit Against Novo Nordisk The acquisition of Metsera Inc. stands as a defining moment in Pfizer’s corporate history during…
Enter the 14-digit code sent to your email.